Aclarion Inc

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The London Clinic is the UK's most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997.

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

Development of This Program Supports Aclarion's Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will not file its Quarterly Report for the quarter ended March 31, 2023 within the filing deadline established by the Securities and Exchange Commission and will be a late filer with respect to such report.

Aclarion, Inc. Announces Delayed 10-Q Filing

Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of Definitive Growth Capital BROOMFIELD, CO, May 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the closing of up to a $2M unsecured, non-convertible debt financing that allows the Company to continue executing on its 2023 plan while providing the runway to achieve three critical milestones ahead of securing definitive growth capital. Brent Ness, CEO of Aclarion, said, “We have been executing really well on multiple fronts.

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain.

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

Aeglea BioTherapeutics

Astra Space

Bionano Genomics

Credit Suisse

Getaround Inc

Canoo

Inpixon

Tempo Automation Holdings Inc

VirnetX

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1

Aclarion shares skyrocketed after the company published data from a two-year trial that demonstrated improved surgical outcomes for discogenic lower back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan, the company's intelligence platform for measuring pain biomarkers in the lumbar spine. Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine and uses its proprietary signal processing techniques to extract and quantify chemical biomarkers associated with disc pain, according to Aclarion.

Aclarion skyrockets on positive trial data for lower back pain intelligence platform

Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?

Penny Stocks to Buy Now? 7 Under $1 To Watch This Week

Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Alpesh Patel, MD, MBA Co-Director of Northwestern Center for Spine Health will advise the company as a key opinion leader (KOL). In addition to his leadership role in the Center for Spine Health, Dr. Patel serves as professor of Orthopaedic Surgery and Neurosurgery at Northwestern University in Evanston, IL.

Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor

BROOMFIELD, CO / ACCESSWIRE / February 16, 2023 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023. Jeff Thramann, Executive Chairman, will present at the conference.

Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023

NociscanTM  is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain.

Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium

Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Gregory Basil, MD, Director of Endoscopic Spine Surgery at the University of Miami will advise the company as a key opinion leader (KOL). Dr. Basil is an award-winning surgeon with particular interest in clinical outcomes through novel, objective innovations. Dr. Basil is also an entrepreneur and co-founder of Kinesiometrics.

Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"),  a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26th.Event: Q1 Investor SummitDate: January 26th, 2023Presentation: January 26th at 12:30 pm ET timeLocation: https://us06web.zoom.us/webinar/register/WN_IyxNcENWRd-KCIMWYg6F6w

Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire  -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and Co-Director of the Combined High Risk Spine Service, the Neurospinal Disorders Program, and the UCSF Spine Center at the University of California at San Francisco will advise the company as a Key Opinion Leader (KOL) nationally.

Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.

Aclarion's Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.

Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration.

Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker

BROOMFIELD, CO / ACCESSWIRE / October 25, 2022 / Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), will be presenting at the 15th annual LD Micro Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles. Executive Chairman, Jeff Thramann will be presenting an overview of the Company and providing a business update.

Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV

BROOMFIELD, CO / ACCESSWIRE / October 24, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the company as a key opinion leader (KOL) nationally.

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

Presentation on Tuesday, October 25th at 9:00 AM PTBroomfield, Colorado--(Newsfile Corp. - October 12, 2022) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today that it will be presenting at the 15th annual Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel.

Aclarion To Present at The LD Micro Main Event XV

Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022 NociscanTM is the first evidence-supported SaaS platform to objectively analyze intradiscal pain Nociscan bridges major diagnostic void between MRI and provocative discography BROOMFIELD, CO / ACCESSWIRE / October 10, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today their participation at the North American Spine Society (NASS) 37th Annual Meeting. Aclarion executives, Brent Ness and Ryan Bond, will be attending the NASS meeting with industry-leading physicians and attending the Case Presentation on the National Institute of Health's Helping to End Addiction Long-term Initiative (NIH HEAL), Wednesday, October 12th at 3PM CT.

Aclarion Announces Participation at the NASS 37th Annual Meeting

Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solution BROOMFIELD, CO / ACCESSWIRE / October 3, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that John Keller M.D., Chief of Neurosurgery at University of Michigan Health-West and Neurosurgeon at Great Lakes Neurosurgical Associates in Grand Rapids, MI, will advise the company as a Key Opinion Leader (KOL) in the greater Michigan market.

John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain NociscanTM to be commercially active across seven participating major academic medical centers BROOMFIELD, CO / ACCESSWIRE / September 19, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their participation in the Biomarkers for Evaluating Spine Treatments (BEST) Trial funded through the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM. BEST will enroll over 800 patients at 12 leading academic teaching institutions across the United States, with a subset of 200 undergoing advanced biomarker profiling, which includes Nociscan.

Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

Broomfield, Colorado--(Newsfile Corp. - August 4, 2022) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that Jeff Thramann, Executive Chairman, and Brent Ness, CEO, will be attending and presenting at the Q3 Virtual Investor Summit.

News for Aclarion Inc Stock (ACON)